---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Place in treatment, anticipated use, and care setting. Topics: Guideline rationale for combination treatment, Guideline recommendation for referral to an expert center, Company-presented positioning of adrabetadex as a foundational therapy combined with other approved treatments, Intended use: early intervention in infantile-onset disease, and 2 further topics. 7 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

- Indication: LEMBAZ is indicated to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in pediatric patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older.
- Position relative to other therapies: before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. In the label's integrated survival analysis, longer overall survival was observed independent of baseline miglustat use. Published recommendations state that all patients with a confirmed diagnosis should be considered for miglustat, those with neurological symptoms for levacetylleucine, and those with neurological symptoms on background miglustat for arimoclomol; more than 75% of participants in the arimoclomol and levacetylleucine pivotal trials were taking miglustat. The company describes adrabetadex as “a foundational therapy that can be safely combined with other approved NPC treatments”, based on a safety profile generally similar with and without additional therapies.
- Anticipated use: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that early intervention can make the greatest difference.
- Care setting: LEMBAZ is administered intrathecally every two weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures, with local anesthetic and sedation as indicated by the patient's clinical condition. A comprehensive audiology evaluation is performed before use. Lembaz is exclusively available through CuraScript SD by Evernorth and is billed in medical buy-and-bill settings without a product-specific HCPCS code. Published recommendations call for referral to a center with expertise in NPC wherever possible.

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [LEMBAZ prior authorization checklist (2026)](https://lembazrx.com/wp-content/uploads/prior-authorization-checklist.pdf); [LEMBAZ billing and coding guide (2026)](https://lembazrx.com/wp-content/uploads/billing-coding-guide.pdf)

<a id="topic-2.2.2.2-2"></a>

### Guideline rationale for combination treatment

> “In both arimoclomol and levacetylleucine pivotal clinical trials, more than 75% of study participants were taking miglustat, highlighting the importance and safety of combination therapy”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.2-3"></a>

### Guideline recommendation for referral to an expert center

> “Wherever possible, patients identified with NPC should be referred to a center with expertise in the care of this condition.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.2-4"></a>

### Company-presented positioning of adrabetadex as a foundational therapy combined with other approved treatments

> “The safety profile of adrabetadex was generally similar with and without the use of additional therapies, supporting its use as a foundational therapy that can be safely combined with other approved NPC treatments.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-2.2.2.2-5"></a>

### Intended use: early intervention in infantile-onset disease

> “For the first time, LEMBAZ gives clinicians a way to address the underlying cholesterol trafficking defect that causes infantile-onset NPC, where early intervention can make the greatest difference.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.2-6"></a>

### Care setting: administration sites and treatment center preparation

> “Proximity to an administration site should never stand between a family and treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

> “Help treatment centers establish the necessary workflows to care for individuals who may receive adrabetadex”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-2.2.2.2-7"></a>

### Emerging NPC treatment paradigm described by a competing cyclodextrin sponsor

> “NPC treatment landscape evolving from no approved therapy to combination regimens”
> “Remibetadex has been designed to have a distinct mechanism of action that removes accumulated cholesterol independent of abnormal NPC protein, complementary to existing therapies”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
